Form 10-Q FIVE PRIME THERAPEUTICS For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Five Prime Therapeutics (FPRX) Misses Q3 EPS by 21c
November 4, 2016 8:12 AM EDTFive Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($0.72), $0.21 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $6.7 million versus the consensus estimate of $7.5 million.
Five Prime continues to expect full-year 2016 net cash used in operating activities to be less... More
